Breast cancer is one of the most common diseases among women worldwide, often referred to as a silent threat that requires urgent and specialized care. A groundbreaking approach in breast cancer treatment, known as Neoadjuvant Therapy (pre-surgery medication), has transformed patient care into a new standard focused on precision and improved outcomes. Namarak Hospital is dedicated to providing this service, adhering to global standards of care.
Diagnosis and Staging
Before starting treatment, physicians conduct a comprehensive diagnosis to determine the cancer’s stage and type. Staging is categorized from Stage 1 to Stage 4 based on tumor size, lymph node involvement, and metastasis to other organs. Breast cancer types are identified via immunohistochemistry, focusing on estrogen receptors (ER), progesterone receptors (PgR), and HER2 receptors. They are broadly classified as:
Hormone receptor-positive
HER2-positive
Triple-negative (lacking both hormone and HER2 receptors)
Traditionally, surgery was the first-line treatment, followed by adjuvant therapy (post-surgery medication). Today, Neoadjuvant Therapy has become a vital treatment strategy, offering multiple advantages over traditional post-surgery therapy. Initially introduced in the 1970s for locally advanced, inoperable breast cancer, it now includes early-stage operable cases as well.
Importance of Neoadjuvant Therapy
Neoadjuvant Therapy provides several benefits compared to traditional approaches:
Tumor Reduction: Increases the likelihood of breast-conserving surgery (BCS). Studies show up to 50% of patients shifted from total mastectomy to BCS after Neoadjuvant Therapy.
Immediate Response Assessment: Enables real-time evaluation of tumor response, allowing physicians to adjust treatment plans accordingly.
Early Systemic Control: Improves the management of undetectable metastases (occult metastases), particularly in HER2-positive and triple-negative breast cancers.
Improved Long-Term Outcomes: Achieving pathological complete response (pCR) – the absence of cancer cells post-treatment – correlates with better long-term outcomes, especially in HER2-positive and triple-negative cancers.
Medications Used in Neoadjuvant Therapy
Chemotherapy: The primary treatment for triple-negative and HER2-positive breast cancers.
HER2-Targeted Therapy: Combining Trastuzumab and Pertuzumab with chemotherapy significantly increases the pCR rate for HER2-positive cancers.
Immunotherapy: Plays a key role in high-risk triple-negative cases, with Pembrolizumab showing promising results as an FDA-approved immunotherapy.
Hormonal Therapy: For HR-positive cancers, combining hormone therapy with CDK4/6 inhibitors has proven effective, particularly in postmenopausal patients.
Patient Selection
Ideal candidates for Neoadjuvant Therapy include:
Locally advanced breast cancer (T3 or T4 tumors)
Cases with lymph node involvement
Early-stage high-risk patients (tumors ≥2 cm, especially triple-negative or HER2-positive)
Patients requiring delayed surgery
Pre-Treatment Preparation
Tumor Localization: Placement of a titanium clip or Scout Radar technology for tracking tumor response and surgical planning.
Genetic and Molecular Profiling: Ensures tailored and precise treatment plans.
Advantages of Neoadjuvant Therapy
Increased Breast-Conserving Surgery Rates: Over 50% of patients transition from mastectomy to BCS.
Clear Prognostic Indicators: Pathological complete response (pCR) serves as a reliable indicator of long-term outcomes.
Reduced Metastasis Risk: The better the tumor’s response, the lower the risk of metastasis.
Why Choose Namarak Hospital?
Global Standard Treatments: Guided by NCCN and ASCO protocols.
Advanced Technology: Includes 3D mammograms, automated ultrasound, genetic testing, and ctDNA analysis.
Expert Medical Team: Specializing in diverse breast cancer cases with extensive experience.
Holistic Care: Comprehensive services from treatment to rehabilitation and quality-of-life improvements.
Conclusion
Neoadjuvant Therapy represents a highly effective approach in breast cancer treatment, improving both surgical and long-term outcomes. Decisions regarding treatment should be made in consultation with a specialized medical team, considering the cancer stage, type, and patient’s overall health
Comments